qfx

Not long past, Lilly’s name rang like a bell in the desert of weight-loss drugs. When Zepbound emerged—a twin to Mounjaro’s diabetes miracle—the company rode high, a modern-day prospector striking black gold. Investors flocked like locusts to a ripe harvest, betting obesity’s endless blight would fill their coffers.

For the North American demesne, revenue is poised to flutter past $365 million, a figure that pirouettes well beyond the company’s prior $345 million choreography and the analysts’ collective murmur of $354 million. This numerical ballet owes its elegance to a troupe of paid subscribers—over 1.35 million strong—trumping the earlier 1.24 million forecast. A similar pas de deux unfolds abroad: $8.5 million in global revenue, outshining the $7 million prologue, with subscribers bowing at 340,000 versus 330,000.

In this quarter’s revelation, Visa not only surpassed the expectations of its investors but unveiled a robust growth narrative—14% increase in revenue and a remarkable 23% rise in earnings per share testify to the remarkable vitality of consumer spending. Here we see a reflection of society’s desires and needs, a testament to human resilience—spending by the populace persists in a world fraught with whispers of uncertainty and impending economic storms.

As the clock struck upon the latest quarterly report, Stanley Black & Decker unveiled revenues totalling a rather balmy $3.9 billion, down 2% from the previous year. Management, those crafty wizards of business, cautioned us about the dreaded sluggish outdoor buying season and a parade of shipment mishaps. These mishaps, as it turns out, were not mere happenstance but rather the bumbling result of tariffs imposed by the current presidential wizardry.